Novavax (NVAX) Misses Q3 EPS, Revenue Beats; Guides to Low End

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Novavax (NVAX) Misses Q3 EPS, Revenue Beats; Guides to Low End

Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights

November 8, 2022 4:02 PM EST

Achieved total revenue for the third quarter of $735 million Delivered over 94 million doses of NVX-CoV2373 globally to dateAuthorized as a booster for adults in the U.S., E.U., and additional markets Authorized as a primary series for adolescents aged 12 17 years in U.S., EU, Japan, and additional markets Announced data about our prototype's broad immune response against circulating variants when used as a booster Initiated NVX-CoV2373 Phase 2b/3 study in children 6 months through 11 years of ageRefining full year 2022 total revenue... More